Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD -1.65%88 EV-to-EBITDA is 8.80 as of Jul. 29, 2026, which is 10% below its 10-year median of 9.73. GuruFocus rates VMD with a GF Score™ of 88/100 and a GF Value™ of $10.99 (Fairly Valued). The stock has 7 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 71.87% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viemed Healthcare's enterprise value is $461.2 Mil.
Viemed Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $52.4 Mil. Therefore, Viemed Healthcare's EV-to-EBITDA for today is 8.80.
The historical rank and industry rank for Viemed Healthcare's EV-to-EBITDA or its related term are showing as below:
VMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.97 Med: 9.73 Max: 26.47
Current: 8.8
During the past 10 years, the highest EV-to-EBITDA of Viemed Healthcare was 26.47. The lowest was 4.97. And the median was 9.73.
VMD's EV-to-EBITDA is ranked better than 71.87% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs VMD: 8.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viemed Healthcare's PE Ratio (TTM) for today is calculated as:
Viemed Healthcare's share price for today is $11.91.
Viemed Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Viemed Healthcare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viemed Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's EV-to-EBITDA falls into.
Viemed Healthcare's current Enterprise Value is $461.2 Mil.
Viemed Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viemed Healthcare (VMD) has a EV-to-EBITDA of 8.80 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viemed Healthcare. This is 10% below median its historical median of 9.73. Over the past decade, Viemed Healthcare's EV-to-EBITDA has ranged from 4.97 to 26.47. According to the industry distribution chart, Viemed Healthcare ranks #144 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 28.1%.
Is Viemed Healthcare's EV-to-EBITDA too high?
Viemed Healthcare's current EV-to-EBITDA of 8.80 is 10% below median its 10-year median of 9.73. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 26.47. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.25. Viemed Healthcare's value of 8.80 is 38.2% below this industry median. Based on the distribution chart, Viemed Healthcare ranks #144 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Viemed Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's EV-to-EBITDA compare to OFIX and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #144 out of 512 companies for EV-to-EBITDA. This puts Viemed Healthcare in the upper half of its industry. The industry median EV-to-EBITDA is 14.25. Viemed Healthcare's value of 8.80 is 38.2% below this benchmark. Historically, Viemed Healthcare's own EV-to-EBITDA has ranged from 4.97 to 26.47 over the past decade. While the company's 10-year median is 9.73 vs. the industry median of 14.25, Viemed Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current EV-to-EBITDA of 8.80 is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viemed Healthcare. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current EV-to-EBITDA is 8.80, which is 10% below median its own 10-year median of 9.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Fairly Valued. The stock's GF Value™ is $10.99, compared to a current price of $11.91 — trading 8.4% above its estimated fair value. The current EV-to-EBITDA is 8.80, which is 10% below median its 10-year median of 9.73 and 38.2% below the Medical Devices & Instruments industry median of 14.25. Viemed Healthcare's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current EV-to-EBITDA is 8.80 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be overvalued.
The current stock price of $11.91 is trading 8.4% above its estimated GF Value™ of $10.99.
GuruFocus considers Viemed Healthcare to be Fairly Valued.
Key valuation signals for VMD:
EV-to-EBITDA: 8.80 (10% below median its 10-year median of 9.73)
GF Value™: $10.99 vs. price of $11.91 (8.4% above fair value)
Industry Position: 38.2% below the Medical Devices & Instruments median (#144 of 512)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
88GF Score
Get the complete analysis for VMD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
